positioned to progress. on Insulet close It and the with another is of We momentum. our performance strong are as good great year incredible afternoon, we exciting an Deb, well and we everyone. time and and operational quarter to financial delivered growth at build continue Thanks,
X to in very and build large Insulet work we and result and the done has unmet Our is the have the to significant for needs, company. Type segments foundation positioned years making the the market, and represent growing strong which address. Both performance diabetes Type a uniquely been powerful of a is X
The same and our people we the in with in international X.X the serve diabetes about Type live huge. is X number today. opportunity markets United Approximately million States
Additionally, insulin the we size Type estimate States the million and million regions. population growing between X with in and that X.X population United international requiring in people similar a our is X
The market complications. with last to which opportunity glycemic is four business opportunities, urgent, executing not our years on targets, lead diabetes achieving transforming people strategic imperatives. have To living unlock we spent can health and the long-term also and because optimal of the many are near couple
has strengthen market expand ensure innovation One, our strategic a which XXXX global prospects. two, footprint; reinforcing these therapy; throughout four, been Pod our our excellence organization. strong consumer-focused with coming in results our in year long-term are Insulet’s imperatives access; and now drive fruition three, our confidence operational and to are
our world. approach significant we diabetes the are everything do people and the to us. the of with on remains focused diabetes the around before execution hard team the of We demonstrates are several we our last the successful started. realize we work and years, are and over getting our returns have investments beginning to on and to community Improving capture lives central delivering right The we just innovations opportunities life-changing the to strategy that
XXXX our will an made the to outlook. turn to we results an the I highlights and provide progress on call, I’ll financial detail of who key quarter discuss discuss overview our Wayde in update call share then strategic imperatives. today’s greater third During over will financial our and
for questions. We will then call open the
our performance. financial with Starting
representing U.S. a million line both our international third throughout exceeding $XX our by our at $XXX generated end global year-over-year. We product increase in was in million outperformed consistently We have guidance with XX% and and was diabetes This and exception. growth by cylinders. quarter firing our XX% revenue, all operations XXXX the driven no revenue high on
I’m imperatives the on focus sustained team’s strategic across and of and mission. our our execution team’s the proud progress
strong fifth growth consecutive fifth XX% net results, positive quarter both our quarter revenue these achieved of With than operating we consecutive our greater and income. of and
In fact, annual than greater fourth XXXX growth. mark consecutive will our year revenue XX% of
outperformance, XXXX, for raising talk we shortly. Given guidance our sustained to Wayde are will again which once
which on to enable innovation our both efforts for expand strategic commercial, increase successfully and advance to coverage third with the we our quarter, I access, we through pharmacy Medicaid to focused begin imperatives. will to In continued Turning coverage Medicare the market and have channel. beneficiaries.
represent Additionally, Medicare beneficiaries. also of Omnipod incredibly percentage and but suited design for Type the our the because population, product Medicare are our increased not growing beneficiaries because coverage insulin-requiring many are a X of to users, of functionality continue only whom well
new increasing model business through impact in model. pay-as-you-go our also and are innovations We product of with our innovation innovation, our both terms our unique also new
cost launched recently several zero for because is Omnipod hurdles DASH disrupter Pod with cost, with we an are advantages access more payers, therapy. to Our and and know adopting upfront exciting unique patients both available people
quarter, to And of number the new in of means model the providing every used by record or channel, many no since otherwise Omnipod launch, adopted not more DASH pharmacy afford Through would we with and technology customers a able be upfront cost have lock-in access are easy-to-use new or DASH’s United this period. far users whom can pay-as-you-go access our to Omnipod This States. be technology. patients,
experience on we will product and seen who Based benefits. patients positive believe and and to on DASH have DASH, on Omnipod long-term that overwhelmingly continue its feedback stay try
and pharmacy provide model cost benefit member also differentiators risk because and of patients true for attrition they payers. are Our reduced and access new
lower long-term cost the the user and and commitment, to therapy, The of complications. low earlier the likelihood Omnipod an in its treatment near feel of can higher greater simplicity, likelihood the Pod earlier and glycemic MDI of low recommending and patients Because confident physicians better adopts number the a of control pathway. health
are simplicity, physicians they DASH more us call, many a Omnipod DASH’s Type technology daily discretion X ease-of-use to multiple last not would X and for and on very population now told therapy. a pump users, have multiple for injection recommended still patients, doctors communicated injections, diabetes. particularly people recommending I Type using As with it make living quarter’s daily appealing beneficial those including have
Market XX% our to helped and vast our users. multiple access starts DASH U.S. quarter. gains injection the and drive business, work of from starts new the starts in majority to commensurate new in came increased of establish typical of daily of represented approximately reimbursement. third with our Growth continues be the new DASH our access third quarter as
going quarter being from XX% our of starts living through pharmacy, significant U.S. quarter with a XX% up a XX% the we saw and And individuals last Type X the quarters new of is to diabetes. now through Additionally, two the for volume increase total in row, second in just XX% the pharmacy our ago. to over XX% percentage
terms bring product in system in development game-changing the In Horizon the our excited automated the and our year. extremely are insulin new innovation, of delivery of of to half we are final stages next Omnipod to second market
a to including a next we incredibly month. we proud This consist three-month study a range, across of designed outpatient track broad individuals on remain and system XXX recruiting pivotals clinical of start age have pediatrics. are for of will We
insulin to system delivery are of weeks. excited We Horizon in people a our send automated home matter with
the provide than first automated be competitive positioned more uniquely other delivery. incredible gone disposable to Horizon’s done smartphone directly have work algorithm the because will the we rather carry Horizon, around. time factor must to architecture unique an user give and AID to put is Horizon’s work our on insulin that into strong deliver devices. our design closed loop, accompanying on Pod device over the form on in With the tubeless, advantages has Pod securing controlled personal the Insulet algorithm Insulet
Our our and the sensor PDM engineering in at teams collaboration highly great our closely phone programs Dexcom great engineering complex to loop. Pod a keep be requiring simple. the design directly enable and worked work experience to or technical to have without user to to closed These require speak colleagues Dexcom with
daily for coming used, require ongoing new can out-of-the-box multiple system. our where easily means users plug offer anyone to Horizon transition is system daily from to actual maintenance. injections. play it optimizes insulin should an designed AID time, Over less on experience insulin be will and Horizon the based automated delivery which even
You in are simply you gets. it put loop. our closed minutes within Pod your as Dexcom in sensor and It’s as simple with
always We is know that burden diabetes can be front a significant of and mind.
needs have exactly are management. We think customized Horizon also will nobody’s personalized approach users the don’t their know diabetes to want same. offer that and about a more diabetes to to
to flexibility the provide peace our is system’s for personalized level of to of of an allow targets multiple the to Horizon select ability is unique and to personalization designed users a level mind. control unparallel glucose of customization. features One and unique give
these design living other People us with and Horizon helped features. diabetes
of the factor human completed our have We midst has feedback our in factor summative and formative human testing terrific. studies been and are
So year. next and we stages thrilled to advanced diabetes community development bring in are work final to of our to the system be the our
Apple product development AID efforts App can open to the continue Tidepool’s addition source be internal on our Store. through own support In we programs, development an accessed loop to that app
to to market. with position cleared goal the Loop patient the and Tidepool be component a choice of collaboration is Omnipod in this Our to FDA support system
globally. Turning to to efforts our expand now
Direct large to in strengthening We Europe in continue operations opportunities. strategic are with a have firmly imperative place making models. of great progress new addressable in and footprint on for unlock markets we business and our year our over sustainable global been geographies
and markets, front new Europe plan Omnipod will of Across need XXXX. there a limited European effective unmet delivery launch runway across next and enthusiastic insulin the us. are our in huge select existing of and release the market for about we is to We in DASH continue in throughout month DASH significant markets, rollout to simple, we
customers enter markets. are we latest the our which exciting prefer with and is to know We platform our DASH technology for new
that vetting potential Our new order conceived. translations, market ensure our strategies in go-to-market strategic on language team partners is to development well and of are working
and Horizon to with step to a to reminder, is bring markets. the our As phone control DASH we plan phone control first international
solidifying rest in markets today. offer will new we international footprint value our the to focused of to in in opportunity. markets into year, remain on we and that a expand ahead position global compelling Looking Beginning which presence look leadership the the we our have will XXXX,
and most not our There prioritizing team strategies. is around world international opportunities is the but the in significant attractive and and need unmet go-to-market interest Europe only
in the not efforts over global will foundation years and add meaningful term. expansion long top While growth we broaden line global our would and our over few strengthen significant next to incremental expansion expect revenue continued the XXXX, contribute
ramp turning to Lastly, excellence of operational manufacturing U.S. and our facility. new the
to operations We high produce landed eventually at and scale continue at cost exceptional, our efficiently, United global to enabling products strengthen States. lower the Insulet quality in
U.S. the in began production we new highly quarter, automated facility Last our at manufacturing
in second are our process mid with product on of production We a of line manufacturing now sellable year. installing this line expected U.S. next
gross manufacturing key track of on remain is we deliver. innovation driver a our of target margin, Our which to XX% XXXX
continued Given growing also rapid poised in Omnipod position our further line growth, will we the for manufacturing strengthen expectations in of launch line globe. are demand operational and install plan U.S. industry-leading for Horizon third XXXX. ensure This and successful the excellence, and we to our to our our will in across a third meet
With over to that, the turn I’ll call Wayde.
